Search research articles
Contact Us
Filters
Showing results (31-40 of 160) with videos related to
Page
of 16
Sort By:
Clinical Case Reports
|
June 12, 2019
Lysozyme nephropathy in chronic myelomonocytic leukemia
Ami B Patel, Rodney R Miles, Michael W Deininger
Cancer Medicine
|
August 9, 2023
Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia
May Garrett, Beverly Knight, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2019
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Dongqing Yan, Anthony D Pomicter, Thomas O'Hare, et al.
BMC Medicine
|
August 27, 2011
Advances in the treatment of chronic myeloid leukemia
Anna M Eiring, Jamshid S Khorashad, Kimberly Morley, et al.
Current Hematologic Malignancy Reports
|
August 31, 2017
Minimal Residual Disease Eradication in CML: Does It Really Matter?
Srinivas K Tantravahi, Raga S Guthula, Thomas O'Hare, et al.
Clinical Lymphoma & Myeloma
|
March 4, 2009
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?
Jennifer L Snead, Thomas O'Hare, Christopher A Eide, et al.
Nature Reviews. Cancer
|
July 25, 2012
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare, Matthew S Zabriskie, Anna M Eiring, et al.
Experimental Hematology
|
March 18, 2006
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia
Shadmehr Demehri, Amie Corbin, Marc Loriaux, et al.
Experimental Hematology
|
October 31, 2003
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate
Alex J Tipping, Michael W Deininger, John M Goldman, et al.
Blood
|
August 23, 2007
Therapeutic drug monitoring in CML patients on imatinib
Carolyn Blasdel, Merrill J Egorin, Theodore F Lagattuta, et al.
Page
of 16
Search research articles
Search
Showing results (31-40 of 160) with videos related to
Sort By:
Page
of 16
Clinical Case Reports
|
June 12, 2019
Lysozyme nephropathy in chronic myelomonocytic leukemia
Ami B Patel, Rodney R Miles, Michael W Deininger
Cancer Medicine
|
August 9, 2023
Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia
May Garrett, Beverly Knight, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2019
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Dongqing Yan, Anthony D Pomicter, Thomas O'Hare, et al.
BMC Medicine
|
August 27, 2011
Advances in the treatment of chronic myeloid leukemia
Anna M Eiring, Jamshid S Khorashad, Kimberly Morley, et al.
Current Hematologic Malignancy Reports
|
August 31, 2017
Minimal Residual Disease Eradication in CML: Does It Really Matter?
Srinivas K Tantravahi, Raga S Guthula, Thomas O'Hare, et al.
Clinical Lymphoma & Myeloma
|
March 4, 2009
New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?
Jennifer L Snead, Thomas O'Hare, Christopher A Eide, et al.
Nature Reviews. Cancer
|
July 25, 2012
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare, Matthew S Zabriskie, Anna M Eiring, et al.
Experimental Hematology
|
March 18, 2006
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia
Shadmehr Demehri, Amie Corbin, Marc Loriaux, et al.
Experimental Hematology
|
October 31, 2003
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate
Alex J Tipping, Michael W Deininger, John M Goldman, et al.
Blood
|
August 23, 2007
Therapeutic drug monitoring in CML patients on imatinib
Carolyn Blasdel, Merrill J Egorin, Theodore F Lagattuta, et al.
Page
of 16